Needham Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Buy rating on Phathom Pharmaceuticals (NASDAQ:PHAT) and maintained a $26 price target.
April 26, 2024 | 3:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer reiterates a Buy rating on Phathom Pharmaceuticals with a $26 price target.
The reiteration of a Buy rating and a maintained price target of $26 by a reputable analyst suggests a positive outlook for Phathom Pharmaceuticals, likely leading to increased investor confidence and potential upward movement in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100